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Objective: We wished to evaluate the effects of inhaled formoterol, a long-acting
b2-adrenergic agonist, on exercise tolerance and dynamic hyperinflation (DH) in severely
disabled chronic obstructive pulmonary disease (COPD) patients.
Design: In a two-period, crossover study, 21 patients with advanced COPD (FEV1 ¼
38.8711.7% predicted, 16 patients GOLD stages III–IV) were randomly allocated to receive
inhaled formoterol fumarate 12 mg twice daily for 14 days followed by placebo for 14 days,
or vice versa. Patients performed constant work-rate cardiopulmonary exercise tests to
the limit of tolerance (Tlim) on a cycle ergometer: inspiratory capacity (IC) was obtained
at rest and each minute during exercise. Baseline and transitional dyspnoea indices
(BDI and TDI) were also recorded.
Results: Eighteen patients completed both treatment periods. Formoterol treatment was
associated with an estimated increase of 130 s in Tlim compared with placebo (P ¼ 0.052):
this corresponded to a 37.8% improvement over placebo (P ¼ 0.012). Enhanced exercise
tolerance after bronchodilator was associated with diminished DH marked by higher
inspiratory reserve and tidal volumes at isotime and exercise cessation (Po0.05). There
was no significant difference between formoterol and placebo on exercise dyspnoeaElsevier Ltd. All rights reserved.
atory Department of Glasgow Royal Infirmary, UK. Novartis Pharma AG, Basel, Switzerland, funded this
5571 8384; fax: +55 11 5575 2843.
.epm.br (J.A. Neder).
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Formoterol and exercise tolerance in severe COPD 2057ratings; however, all domains of the TDI improved (Pp0.02) following formoterol,
compared with placebo.
Conclusion: Inhaled formoterol 12 mg twice daily is effective in ameliorating DH, daily
dyspnoea and exercise intolerance even in patients with advanced COPD.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by long-term, partially reversible, airways obstruction.1
Exercise intolerance is a hallmark of the disease, being
commonly associated with incapacitating dyspnoea, re-
duced quality of life and increased morbidity and mortal-
ity.2,3 Increased end-expiratory lung volume (EELV) is
commonly found during progressive exercise in flow-limited
patients as ventilatory requirements increase.4–7 This
dynamic hyperinflation (DH) accommodates higher levels
of airflow and therefore ventilation ( _VE). However, as there
appears to be no associated increase in total lung capacity
(TLC),8 tidal volume (VT) becomes elevated on to the poorly
compliant upper region of the thoracic pressure–volume
relationship, resulting in a substantially increased elastic
work of breathing and exacerbated dyspnoeic sensation.7,9
Reductions in DH during high-intensity constant work
rate (WR) exercise can improve exercise tolerance,
whether consequent to a reduction in ventilatory require-
ment10,11 or to a decreased mechanical time constant of
the lung.12–15
Formoterol is a potent b2-adrenoceptor agonist with a
rapid-onset, long-acting effect.16 Several studies have found
that formoterol treatment is associated with beneficial
effects on resting pulmonary function and quality of life in
patients with COPD.17,18 However, there are few data extant
regarding its effect on exercise tolerance and DH in COPD,
especially in patients with more advanced disease. Aalbers
et al.,19 for instance, were unable to demonstrate any
significant improvement in incremental shuttle-walking test
distance following formoterol. Liesker et al.20 reported a
modest beneficial effect of formoterol on symptom-limited
incremental exercise performance with peak WR increasing
by only about 5W. However, incremental exercise perfor-
mance measures often prove relatively insensitive for
detection of interventional changes in COPD patients,
in contrast to those from symptom-limited constant
WR paradigms such as time to the limit of tolerance
(Tlim).21,22
In this context, to our knowledge, no previous study has
evaluated the potential effects of inhaled formoterol in
enhancing sub-maximal exercise tolerance and DH in
severely disabled patients. This would seem to constitute
a clinically relevant and timely research question, as
few effective pharmacological alternatives are currently
available for these patients.23 Moreover, two recently
published meta-analyses have concluded that there is a
lack of evidence for a beneficial effect of long-acting
bronchodilators in ameliorating exercise impairment in
patients who are poorly responsive to a short-acting
bronchodilator.24,25Our aim, therefore, was to investigate whether formote-
rol, as compared with placebo, would improve Tlim in
severely disabled COPD patients. We also evaluated whether
formoterol would reduce DH and effort-related breath-
lessness during activities of daily living.
Methods
Subjects
Twenty-one subjects (14 males, aged 42–75, body mass
index ¼ 24.875.1 kgm2) with stable COPD (forced expira-
tory volume in 1 s [FEV1]/forced vital capacity [FVC]p60%,
FEV1 o60% predicted and post-bronchodilator FEV1 change
o12% predicted) were randomized (Table 1). Main exclusion
criteria were: recent exacerbation, long-term oxygen
therapy or arterial oxygen saturation o85% at rest, and
treatment with oral corticosteroids, anticholinergics and
antihistamines. All subjects gave written, informed consent
(as approved by the Institutional Medical Ethics Committee).
Study design
This was a single-centre, randomized, double-blind, place-
bo-controlled, crossover trial. Patients were assigned to 14
days of formoterol dry powder capsules 12 mg twice daily
(Foradils Aerolizers; Novartis Pharma AG, Basel, Switzer-
land) followed by 14 days of matching placebo twice daily,
or vice-versa (Fig. 1), separated by a washout of at least
2 days.
Before screening, patients discontinued short- and long-
acting b2-agonists (LABAs) and inhaled anticholinergics.
During the study, patients were given a Combivents
metered-dose inhaler (salbutamol 100 mg/ipratropium bro-
mide 20 mg per actuation, Boehringer Ingelheim GmbH,
Ingelheim, Germany) as rescue medication. Use of inhaled
or nasal corticosteroids and oral modified-release theophyl-
line or derivatives was allowed provided dose, schedule and
formulation remained unchanged.
Protocol
After screening (visit 1), patients returned four times to the
exercise laboratory at the start and end of each treatment
period (visits 2–5) (Fig. 1). At visit 1, they underwent clinical
evaluation, a questionnaire of activity-related breathless-
ness (baseline dyspnoea index: BDI),26 pulmonary function
testing, and a symptom-limited incremental cardiopulmon-
ary exercise test (incCPX). Subjects performed a series of
constant WR CPX (ctCPX) tests to the Tlim, each on a
separate visit (visits 2–5). Changes in daily breathlessness
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Fig. 1 Study design.
Table 1 Resting functional characteristics of the 21 COPD patients (14 males).
Mean (SD) Interquartile range
Spirometry
FEV1, L 1.00 (0.34) 0.78–1.04
FEV1, % predicted 38.8 (11.7) 30.5–49.5
FEV1 reversibility, % predicted 5.5 (3.3) 3.0–8.2
FEV1 reversibility, % baseline 14.3 (8.9) 9.4–19.7
FVC, % predicted 83.8 (18.1) 71.5–95.6
FEV1/FVC, % 37.5 (7.0) 32.8–40.3
Lung volumes
IC, % predicted 73.7 (16.0) 61.2–86.5
RV, % predicted 203.4 (63.1) 150.8–244.7
TLC, % predicted 123.0 (15.5) 117.1–131.1
RV/TLC 0.60 (0.11) 0.55–0.69
IC/TLC 0.27 (0.07) 0.20–0.32
Maximal inspiratory pressure
Absolute values (cmH2O) 54.2 (19.5) 37.0–70.5
Relative values (% predicted) 56.4 (19.0) 45.3–72.2
Lung diffusing capacity
Absolute values (mLmin1mmHg1) 10.2 (4.4) 7.8–14.6
Values measured at screening visit. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; IC: inspiratory capacity; RV:
residual volume; TLC: total lung capacity.
J.A. Neder et al.2058(transition dyspnoea index: TDI)13 were assessed at the end
of each treatment period (Fig. 1).Pulmonary function tests
Resting lung function testing was performed using a
constant-volume body plethysmograph (V6200, SensorMe-
dics Corporation, Yorba Linda, CA, USA). Measurements
were expressed at body temperature and pressure, satu-
rated conditions (BTPS). FVC (L) and FEV1 (L) were measured
before and 20min after inhalation of salbutamol 400 mg via
metered-dose inhaler at visit 1; and before and after
formoterol or placebo on visits 2–5. Post-dose spirometry
was performed within the first 2 h post-dose. Maximalvoluntary ventilation (MVV, Lmin1) was estimated as
FEV1 40. Residual volume (RV, L) and total lung capacity
(TLC, L) were measured. The single breath transfer factor
for carbon monoxide (DLCO, mLmin
1mmHg1) was mea-
sured using the Transflow System (Model 540, Morgan
Medical, Kent, UK). Testing procedures and reference values
were those proposed by Quanjer et al.27Exercise tests
Cardiopulmonary exercise tests (CPX) were performed on an
electromagnetically braked cycle ergometer (Corival, Lode
BV, Groningen, The Netherlands) with subjects maintaining a
pedalling frequency of 6075min1. Subjects breathed
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tube flowmeter. Pulmonary gas exchange and ventilatory
variables were obtained breath-by-breath from calibrated
signals derived from the flowmeter and rapidly responding
gas analysers (CardiO2 System, Medical Graphics Corpora-
tion, St. Paul, MO, USA). Oxygen uptake ( _VO2 , mLmin
1
STPD); ventilation ( _VE, Lmin
1 BTPS); tidal volume (VT, L)
and breathing frequency (f, min1) were recorded and
expressed as 15-s means. Heart rate (HR, min1) was
determined from the R–R interval of a 12-lead electro-
cardiogram (CardiO2 System, Medical Graphics Corporation,
St. Paul, MO, USA) and arterial oxyhaemoglobin saturation
(SpO2) by pulse oximetry (Minolta, Stowood Scientific
Instruments, Oxford, UK). Subjects rated their shortness of
breath and leg effort using the 0–10 Borg scale.28Incremental CPX
The protocol for incremental CPX comprised: (i) 2min at
rest; (ii) 1–3min of unloaded pedalling; (iii) an incremental
phase and (iv) a recovery phase of unloaded pedalling.
During phase (iii), WR was incremented at a constant rate to
the Tlim: the incrementation rate was individually selected
for an incremental duration of 8–12min.29 Peak _VO2 values
(average of final 15 s of incremental phase) were compared
with those predicted by Neder et al.30 The WR incrementa-
tion rate ranged between 2 and 10Wmin1, depending on
judgements regarding patient fitness, with the aim of
reaching the Tlim in approximately 10min.31 Borg scores
for breathlessness and leg effort were obtained at the end of
the incremental phase.28Constant WR CPX
At separate visits at the start and end of the treatment
periods (visits 2–5, Fig. 1), patients undertook four different
constant WR exercise tests to the Tlim. The protocol
comprised: (i) 4min at rest; (ii) 1–3min of unloaded
pedalling; (iii) a loaded phase at a WR (imposed abruptly
and without warning) approximately 80% of the peak WR
obtained in the incremental test and (iv) a recovery period
of unloaded pedalling. The patients rated shortness of
breath and leg effort each min (before the inspiratory
capacity [IC] manoeuvres; see below). Time to intolerance
(Tlim) was the interval between the imposition of the WR
and the point when the subject could no longer maintain the
required pedalling rate (at least 50min1 for 10 s or more)
despite active encouragement. In order to analyse the
data at a standardized exercise time across tests of
widely different durations, an isotime point (Tiso) was
identified for each patient as the shortest exercise duration
successfully completed during either treatment period.
Patients were not told for how long or at what WR they
had exercised.
Changes in IC were used to track alterations in opera-
tional lung volumes.4–7 Assuming constant TLC at the resting
value during exercise,8 changes in IC were taken to reflect
changes in EELV (i.e. EELV ¼ TLC–IC); and inspiratory
reserve volume (IRV) was calculated as TLC–(EELV+VT).
Having been familiarized with the IC manoeuvre at rest,
patients were instructed to breathe normally during
exercise and, after a verbal cue, to inspire maximally (with
verbal encouragement) after a normal exhalation, followedby a relaxed expiration. IC manoeuvres were performed
during the resting period until at least three reproducible
efforts were recorded, i.e. within 10% of the largest
acceptable value,4–7 and each minute during exercise. When
subjects indicated that they could not exercise any longer,
an end-exercise IC effort was recorded. Breathlessness and
leg effort scores were obtained each min before the IC
manoeuvres.
Statistical analysis
The primary efficacy variable was the time to the limit of
exercise tolerance (Tlim). Analysis of covariance (ANCOVA)
was used to test for a significant difference in Tlim for
formoterol versus placebo, using a model that fitted the
factors: treatment sequence (formoterol/placebo or place-
bo/formoterol), patient (nested within sequence), treat-
ment period (1 or 2) and treatment group (formoterol or
placebo), with the period baseline Tlim as a covariate. The
period baseline Tlim was the value measured immediately
before the first dose of treatment in a given period. A 5%
significance level was used. The intent-to-treat population
was defined as all randomized patients who received at least
one dose of trial treatment. However, owing to the crossover
design of the trial, only patients who had measurements of
Tlim available for both periods pre-dose at baseline, and
after approximately 2 weeks of treatment, were included in
the analysis.
Secondary efficacy variables and exploratory variables
were analysed with a similar ANCOVA. For all parametric
analyses (as described above) the estimated difference
between formoterol and placebo was calculated as the
difference between the least squares (adjusted) means for
the two treatments. Some secondary variables were
analysed using the Koch non-parametric method for a two-
period crossover design.32 For these, the estimate of the
median difference between treatments (Hodges–Lehmann
estimator) and associated 95% confidence intervals are
presented.33
At the time of planning, no suitable data on variability
were available from studies using the same exercise
protocols as were used in the present study. Based on
knowledge of the patient population and the exercise test
being used, it was considered that 26 patients, with the aim
of having 20 evaluable patients for the primary analysis,
would be appropriate.
Results
Patient characteristics
Twenty-one patients were randomized: 18 of them com-
pleted both treatment periods. Two patients discontinued
while using placebo owing to increased breathlessness, and
one patient withdrew while receiving formoterol because of
unacceptably high use of rescue medication (more than 8
puffs day1).
Clinical and functional characteristics at baseline were
compatible with advanced COPD: 16/21 patients (76%) were
classified as GOLD stages III–IV1 and the BDI scores (BDI)26
indicated higher levels of disability; the percentages of
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J.A. Neder et al.2060patients with the two most severe grades (Grade 0 or 1)
were 33% (functional impairment), 48% (magnitude of task)
and 71% (magnitude of effort). As expected from the
inclusion criteria, patients presented with severe chronic
airflow limitation: 15/21 patients (71%), for instance, had
FEV1 values below 40% of predicted or 1 L. Median
reversibility was 12%, although only four of the 21 patients
(19%) met ATS/ERS criteria34 for clinically significant
reversibility (values 412% and 200mL compared with
baseline), i.e. in terms of meeting both percent and
absolute increases. Resting hyperinflation and air trapping
were found in most patients: IC/TLC ratio (‘inspiratory
fraction’) was severely reduced (o0.28)35 in 10 subjects
(47%) (Table 1).Tolerance to symptom-limited incremental exercise
In line with the resting data, patients also showed a
severe reduction in maximal exercise capacity: median
(interquartile range) values of peak VO2 and WR were
only 44.5 (38.0–56.5)% predicted and 41 (31.5–54.5)%
predicted, respectively. Ventilatory limitation—at least as
suggested by a VEmax/MVV ratio 40.8
36—was not found
in a sizeable number of patients (9/21 or 43%). Peak leg
effort scores were similar to dyspnoea ratings (median
[interquartile range] ¼ 7 [5–9] vs. 7 [5–8]). In fact, only in
5/21 patients (24%) was dyspnoea the main limiting
symptom.Table 2 Effects of formoterol and placebo on rest and exercis
Formoterol
(adjusted meana)
Placebo
(adjusted
Rest
IC, L 2.23 1.95
EELV, L 4.84 5.13
IRV, L 1.47 1.16
Isotime exerciseb
IC, L 1.76 1.54
EELV, L 5.17 5.30
IRV, L 0.59 0.40
VT, L 1.16 1.03
Borg dyspnoeac 4.5 7.0
Borg leg effortc 6.5 7.0
Exercise cessation
Tlim, s 479 349
Tlim, % change from baseline 29.7 –8.2
IC, L 1.62 1.48
EELV, L 5.49 5.62
IRV, L 0.47 0.36
VT, L 1.12 1.00
Borg dyspnoeac 9.0 7.0
Borg leg effortc 9.0 8.5
EELV: end-expiratory lung volume; IC: inspiratory capacity; IRV: inspi
volume.
aAdjusted means are the treatment means adjusted for the terms
bIsotime median (range) was 197 (25–975) s at a median (range) w
cMedians and Hodges–Lehmann estimator displayed.Effects of formoterol on resting variables
Formoterol inhalation, but not placebo, was associated with
a slight increase in resting FEV1 both on day 1 (increase in
mean ¼ 0.15 L vs. 0.03 L, respectively) and day 14 (increase
in mean ¼ 0.12 L vs. 0.02 L). The changes in mean FEV1 from
baseline (pre-dose on day 1) to post-dose on day 14 were
0.96 to 1.11 L (formoterol) and 0.99 to 0.97 L (placebo).
Formoterol also increased resting IC in 15/18 patients (83%),
compared with 7/17 (41%) patients following placebo;
consequently, EELV was lower post-formoterol than after
placebo (P ¼ 0.001, Table 2). Considering that there were
no significant changes in resting VT after either treatment,
IRV ( ¼ TLC–[EELV+VT]) values increased after formoterol
relative to placebo (P ¼ 0.044, Table 2). Importantly, there
was a significant reduction in all domains of the TDI after
formoterol treatment (estimated treatment difference ¼ 1
to 1.5 for all domains; P ¼ 0.004 for ‘functional impairment’
and P ¼ 0.022 and 0.019 for ‘magnitude of effort’ and
‘magnitude of task’, respectively).Effects of formoterol on constant WR exercise
During placebo treatment, progressive DH was evident over
the course of the symptom-limited constant WR test (Fig. 2):
EELV averaged 5.6270.18 L at Tlim vs. 5.1370.18 L at rest
(Table 2). Consequently, IRV decreased from 1.1670.39 L at
rest to 0.3670.17 L at exercise cessation (Table 2).e responses (n ¼ 18).
meana)
Estimated treatment
difference
(formoterol–placebo)
95% confidence
intervals
P-value
0.28 0.13, 0.42 0.001
–0.29 –0.45, –0.14 0.001
0.31 0.01, 0.61 0.044
0.22 0.07, 0.38 0.009
–0.12 –0.27, 0.02 0.083
0.20 0.09, 0.30 0.002
0.14 0.06, 0.22 0.003
1.5 –2.50, 0.50 0.083
–1.0 –2.00, 0.50 0.161
130 –1.18, 261.79 0.052
37.8 9.43, 66.24 0.012
0.14 0.01, 0.27 0.032
–0.13 –0.27, 0.00 0.045
0.11 0.02, 0.23 0.087
0.12 0.04, 0.20 0.008
0 –1.00, 1.00 0.938
0.5 –1.00, 2.00 0.474
ratory reserve volume; Tlim: time to limit of tolerance; VT: tidal
contained in the statistical analysis (ANCOVA) model.
ork rate of 45.0 [25–170]W.
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Fig. 2 Responses (mean7SD) of operational lung volume after
formoterol and placebo at rest (post-dose), isotime and Tlim.
Formoterol was associated with decreased end-expiratory lung
volume (EELV), both at rest and during exercise. TLC: total lung
capacity; VT: tidal volume; EILV: end-inspiratory lung volume.
Fig. 3 Individual values of Tlim: (a) as absolute values at
baseline and post-treatment (horizontal bars represent med-
ians); and (b) as % change with formoterol vs. % change with
placebo.
Formoterol and exercise tolerance in severe COPD 2061Formoterol was associated with an increase in Tlim of
130 s compared with placebo (P ¼ 0.052; Table 2). Fig. 3a
illustrates the wide inter-individual differences in baseline
Tlim values (45–1245 s across both treatments) and provides
a clear suggestion that the change from pre- to post-dose
Tlim (whether an increase or a decrease) increases with the
baseline value, for both treatments. It may therefore be
more appropriate to consider the change in Tlim from
baseline in percentage terms (Fig. 3b), which shows a 37.8%
difference in favour of formoterol (P ¼ 0.012; Table 2).
These beneficial effects were related to a significantly
greater IC at isotime and Tlim vs. placebo: they were
roughly equivalent to those found at rest (Po0.05) (Fig. 2,
Table 2). Consequently, the corresponding EELV values were
significantly lower with formoterol than with placebo to a
similar extent (i.e. by 0.12 L at isotime and 0.13 L at Tlim)
(Fig. 2, Table 2). In addition, there were significantly greater
VT and IRV values at isotime and Tlim following formoterol
(Table 2). There was no significant treatment effect on
dyspnoea scores at exercise cessation, however (P40.05).
Baseline Tlim values were comparable for the formoterol
and placebo treatment periods (formoterol mean [SD] 394.3
(333.9) s; placebo mean [SD] 398.4 [300.3] s). Baseline
values for Periods 1 and 2 were also similar, indicating that
the washout allowed between treatment periods was
adequate.
Discussion
We set out to investigate the effect of a LABA bronchodi-
lator, formoterol, on submaximal exercise tolerance in
patients with advanced COPD. The study drug was asso-
ciated with a number of significant improvements in both
perceptual and physiological responses, including lower
daily breathlessness, reduced lung operating volumes and
a deeper breathing pattern during exercise. These beneficial
effects translated into an improved tolerance to cycleergometer exercise (i.e. prolonged time to Tlim expressed
as a percentage change). This is, to our knowledge, the first
study to demonstrate the beneficial effects of formoterol on
exercise endurance and DH in patients with severe to very-
severe COPD—a specific sub-population where the advanta-
geous clinical effects of LABAs are still controversial.24,25Effects of bronchodilators on exercise tolerance in
COPD
Inhaled bronchodilators are the cornerstone of the treat-
ment of COPD.1 Although the criteria for a ‘positive’
response to bronchodilators at rest are debatable,37 most
investigators would agree that a decrease in the magni-
tude of DH during exertion is frequently associated with
clinically meaningful outcomes in these patients. In this
context, several authors have found that either short-acting
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J.A. Neder et al.2062or long-acting bronchodilators were able to increase
exercise tolerance, especially by reducing DH in COPD
patients who were, on average, moderately impaired with
some degree of resting ‘flow’ and/or ‘volume’ response to
bronchodilators.4–6,38–40
In the present study, we did find a significant decrease in
EELV after formoterol, associated with higher exercise tidal
and IRVs (Table 2). These changes may have allowed our
hyperinflated patients to breathe over a more compliant
portion of their thoracic pressure–volume curves and,
therefore, to increase their VT (for the same transpulmonary
pressure increment) during exercise, i.e. an improved
neuromechanical coupling.5,6,41 Interestingly, there was a
shift of the operating lung volume range towards lower
values at rest which was maintained throughout the exercise
(Fig. 2). These data suggest that bronchodilators may act
mainly by effecting reductions in lung volumes at rest
that are essentially sustained during subsequent exercise,
rather than by changing the rate of development of effort-
related DH.41Exercise improvement after bronchodilation in
advanced COPD: reasons for response
heterogeneity
A particularly noticeable finding of the present study was
the relatively modest increase in exercise tolerance found in
the group as a whole, despite the beneficial effects on the
respiratory-mechanical properties (Table 2). In this context,
it is important to note that there was a large inter-subject
variability in Tlim and, more importantly, a clear suggestion
that changes in Tlim after either intervention were
proportional to baseline Tlim, i.e. patients with higher
baseline values had greater changes in Tlim and vice-versa
(Fig. 3). When we allowed for this confounding feature by
comparing the percentage change in Tlim (Table 2), results
showed unequivocally that formoterol was associated with
greater improvement in exercise tolerance as compared
with placebo.
A further likely contributor to the inter-subject variability
in Tlim relates to the location of the selected WR relative to
‘critical power’, i.e. the power asymptote on the relation-
ship between power and its sustainable duration (Tlim). In
COPD patients, critical power occurs at approximately 80%
of the difference between the lactate threshold and peak
_VO2 but, importantly, has been shown to be quite vari-
able.42,43 Furthermore, because of the hyperbolic shape of
the power–duration relationship, the magnitude of improve-
ment to a given functional change (here, induced by
formoterol) will be much larger for a WR just above critical
power than for one that is appreciably higher.44 However,
the constraints of our study design precluded the inclusion
of the necessary additional constant-WR tests required to
estimate critical power.42,43
Although the magnitude of change in Tlim (even as a %
increase) was smaller than that reported in some overtly
positive studies involving other bronchodilators in patients
with less severe disease,4–6,38–40 it is important to note that
we evaluated a selected group of severely impaired patients
(Table 1). In this context, it is noteworthy that, despite the
advanced pulmonary abnormalities, exercise leg effortscores were equivalent to dyspnoea ratings at peak exercise
cessation (Table 2). Pepin et al.,45 for instance, recently
showed that walking is a more sensitive exercise modality to
evaluate the response to bronchodilators than cycling in
patients with COPD. This may be especially true for patients
with advanced disease in whom skeletal muscle dysfunction
is more prevalent.1 We may therefore speculate that
peripheral muscle limitation has prevented some of our
more severe patients from cycling for longer after active
drug treatment. Additional studies, therefore, are war-
ranted to further evaluate whether the effects of LABAs in
severe COPD patients would be better advanced by using
upright exercise, without the postural constraints associated
with cycle ergometry.45
Other studies have also reported that the improvement in
exercise capacity in subjects with poorly reversible airflow
limitation is usually smaller than is found in patients with
less severe COPD.46,47 In fact, Man et al. found that
salmeterol was ineffective in improving exercise endurance
time in severe patients (FEV1 ¼ 30.3% predicted) with
‘irreversible’ airways obstruction (o10% FEV1 improvement
from baseline).47 A recently published Cochrane review
also concluded that there is not sufficient evidence for a
significant effect of LABAs on exercise tolerance in patients
who are not particularly responsive to short-acting bronch-
odilators.25 Several hypotheses could be put forward to
explain why the improvement in DH may not be readily
translated into an increased exercise tolerance in advanced
COPD: (i) exercise capacity may have been limited (or
constrained) by other mechanisms, including peripheral
factors (see above) and/or haemodynamics; (ii) the extent
of DH amelioration may have not been sufficient to impact
upon exercise tolerance in some hyperinflated patients with
functionally weak respiratory muscles;47 (iii) the negative
effect of volume history on airway calibre due to deep
inhalations during exercise (i.e. IC manoeuvres) may have
offset pharmacologically induced bronchodilation;48 (iv) as
the relationship between dyspnoea and DH is not linear,13
these patients may need a relatively large improvement in
DH for a measurable decrease in exercise breathlessness;
and, importantly, (v) severely impaired patients with chronic
dyspnoea may not be as motivated as less disabled patients
to exercise to the point of limiting breathlessness—even
after active bronchodilation.Study limitations
An important limitation of the present study was the
relatively small sample size. This is relevant considering
the large inter-subject variability in endurance time. It is
advisable, therefore, that future studies involving patients
with severe to very severe COPD use larger samples to
overcome this shortcoming. As noted earlier, a large muscle-
mass exercise modality other than cycle-ergometry (e.g.
walking) might have proved more sensitive in discriminating
increased exercise tolerance after bronchodilation.45 In
addition, the dissociation between daily breathlessness via
BDI scores (improved) but unaltered exercise dyspnoea
ratings suggests that a formal laboratory-based exercise test
may not be the ideal strategy to demonstrate the beneficial
effects of LABAs in such severely disabled patients.
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Formoterol and exercise tolerance in severe COPD 2063Conclusions
This study has demonstrated, for the first time, that inhaled
formoterol is able to reduce the level of resting and
exercise-related DH with consequential benefits on effort
tolerance and breathlessness on daily living in severely
disabled patients with advanced COPD. These data are of
particular clinical relevance since few effective pharmaco-
logical alternatives are currently available for severely
disabled patients with incapacitating dyspnoea.Acknowledgements
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